40 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
carryforwards could expire unused and be unavailable to offset our future income tax liabilities. In addition, under Sections 382 and 383 of the Internal … - change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. In 2021, we
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
22 Feb 24
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:15am
2023 and completion of research activities for a target under the collaboration agreement with Biogen, partially offset by the completion of research
8-K
EX-99.1
5ws 90wsb
8 Aug 23
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
7:09am
ARS
34e8biluoddfc
28 Apr 23
Annual report to shareholders
7:03am
8-K
EX-99.1
7172eb2xp8nzic2
4 Aug 22
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:15am
8-K
EX-99.1
2xcm34pyf
24 Feb 22
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
7:30am
8-K
EX-99.1
te1v0qalypw
10 Nov 21
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
4:12pm
8-K
EX-99.1
8d1g0
11 Aug 21
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
4:07pm
424B4
7mzbr69tbgfirsihf5
21 Jun 21
Prospectus supplement with pricing info
8:08am